Atea Pharmaceuticals Inc expected to post a loss of 37 cents a share - Earnings Preview

Reuters
02-25
Atea Pharmaceuticals Inc <avir.oq> expected to post a loss of 37 cents a share - Earnings Preview </avir.oq>
  • Atea Pharmaceuticals Inc AVIR.OQ AVIR.O is expected to show no change in quarterly revenue when it reports results on February 26 (estimated) for the period ending December 31 2024

  • ​LSEG's mean analyst estimate for Atea Pharmaceuticals Inc is for a loss of 37 cents per share.

  • The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy," 1 "hold" and 1 "sell" or "strong sell."

  • The mean earnings estimate of analysts was unchanged in the last three months. ​

  • Wall Street's median 12-month price target for Atea Pharmaceuticals Inc is $6.20​, above​ its last closing price of $3.09. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Sep. 30 2024

-0.46

-0.49

-0.37

Beat

25.3

Jun. 30 2024

-0.76

-0.76

-0.48

Beat

37.3

Mar. 31 2024

-0.63

-0.61

-0.75

Missed

-23.6​

Dec. 31 2023

-0.49

-0.50

-0.47

Beat

5.4

​​Sep. 30 2023

-0.45

-0.48

-0.40

Beat

16.1

Jun. 30 2023

-0.45

-0.47

-0.34

Beat

27.7​

Mar. 31 2023

-0.47

-0.48

-0.43

Beat

9.9

Dec. 31 2022

-0.44

-0.45

-0.41

Beat

8.9

This summary was machine generated February 24 at 22:19 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10